Viridian Reports Positive Phase III REVEAL-2 Data for Elegrobart in Chronic Thyroid Eye Disease

Why It Matters

The data offer the first late‑stage evidence of a convenient, subcutaneous treatment that could shift chronic TED management from infusions to self‑administered therapy, expanding market access and addressing an unmet patient need.

Key Takeaways

• Elegrobart achieved 50-54% proptosis response vs 15% placebo.
• Diplopia responders reached 55-61% versus 38% with placebo.
• Safety profile mild; no serious treatment‑related adverse events reported.
• FDA BLA filing targeted for Q1 2027 following trial success.
• Subcutaneous autoinjector aims to enable at‑home chronic TED therapy.

Pulse Analysis

Chronic thyroid eye disease remains one of the most debilitating autoimmune disorders affecting the orbit, with patients often enduring proptosis, double vision and disfiguring eye bulging for years. Current options are limited to high‑dose steroids, orbital radiotherapy, or intravenous biologics such as teprotumumab, which require frequent clinic visits and carry notable safety concerns. The unmet need for a convenient, long‑acting therapy has spurred biotech investment, and Viridian’s elegrobart—engineered for subcutaneous delivery and extended half‑life—directly addresses this gap by offering a potentially at‑home regimen.

The REVEAL‑2 trial enrolled 204 chronic TED patients and randomized them to elegrobart every four weeks, every eight weeks, or placebo. Both dosing arms achieved statistically significant improvements: proptosis reductions of roughly 2 mm and combined responder rates above 45%, compared with 15% for placebo. Diplopia, a key quality‑of‑life metric, improved in more than half of treated patients, with complete resolution in up to 44% of the Q4W cohort. Safety signals were modest; hearing impairment rates stayed under 9% and no serious drug‑related events emerged, reinforcing the drug’s tolerability profile observed in earlier studies.

Regulatory momentum is now building. Viridian intends to submit a biologics license application to the FDA in early 2027, while also pursuing EMA approval, positioning elegrobart to capture a sizable share of the estimated $1.2 billion global TED market. The planned autoinjector could differentiate the product by reducing infusion costs and improving patient adherence. Moreover, the company’s parallel development of veligrotug, another IGF‑1R antagonist, suggests a broader pipeline that may consolidate Viridian’s foothold in autoimmune ophthalmology, potentially reshaping treatment standards for chronic TED patients worldwide.